Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPAVR
2023-504731-40-01Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in aortic stenosis (AS) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Change in left ventricular mass index. Started Nov 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on 2023-504731-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504731-40-01.